214 results on '"Wassenberg, Siegfried"'
Search Results
2. Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
3. Nachruf Dr. med. Thomas Karger (28.02.1948–27.10.2023)
4. Correction: Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA)
5. Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA)
6. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
7. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial
8. Current data on rheumatological care: annual report from the National database (NDB) of the regional collaborative arthritis centres in Germany
9. Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany
10. Nachruf Dr. med. Thomas Karger (28.02.1948–27.10.2023)
11. Correction: Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA)
12. The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis: Individual Patient Data From Five Randomized Trials
13. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
14. Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis
15. Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
16. Standardpräsentation 2021
17. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
18. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)
19. Fluorescence-optical imaging as a promising easy-to-use imaging biomarker to increase early psoriatic arthritis detection in patients with psoriasis: a cross-sectional cohort study with follow-up
20. Unterschiede zwischen allein- oder in Gemeinschaft lebenden Patient:innen mit entzündlich-rheumatische Erkrankungen
21. Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA)
22. Association Between Rheumatoid Arthritis Disease Activity and Periodontitis Defined by Tooth Loss: Longitudinal and Cross‐Sectional Data From Two Observational Studies
23. The Efficacy of Short‐Term Bridging Strategies With High‐ and Low‐Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double‐Blind, Randomized, Placebo‐Controlled Trial
24. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice
25. Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational study
26. P192 Efficacy of filgotinib in rheumatoid arthritis by age, body weight, body mass index: post hoc subgroup analysis of two phase 3 trials
27. Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care
28. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs
29. Improved radiological outcome of rheumatoid arthritis: the importance of early treatment with methotrexate in the era of biological drugs
30. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study
31. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
32. Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
33. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
34. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
35. Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
36. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial
37. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative Arthritis Centres
38. Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
39. Charakterisierung von Psoriasis-Patienten mit subklinischen Zeichen der muskuloskelettalen Entzündung ermittelt durch Fluoreszenz-optische Bildgebung und Überprüfung des Befundes mittels MRT - Analyse der prospektiven multizentrischen XCITING Studie
40. Charakteristika von Patienten mit rheumatoider Arthritis ohne DMARD-Versorgung: Daten aus der Kerndokumentation
41. Gesundheitsökonomische Analyse sowie Berechnung von direkten medizinischen und indirekten Kosten bei Patienten mit RA, PsA und AS im deutschen Praxisalltag - Evaluation der nicht-interventionellen Studie GO-NICE
42. Einfluss der Kombinationstherapie von Rituximab und Lefluonmid auf Patient-Reported Outcomes und Funktion in Patienten mit Rheumatoider Arthritis: Ergebnisse einer multizentrischen, randomisierten, Placebo-kontrollierten Investigator initiierten Studie (AMARA-Study)
43. Detektion von klinisch manifester Arthritis mittels klinischer Untersuchung und subklinischen Zeichen von Entzündung mittels Ultraschall und Fluoreszenz-optischer Bildgebung in Psoriasis-Patienten mit Risikokonstellation für das Auftreten einer Arthritis - Ergebnisse der prospektiven multizentrischen XCITING Studie
44. Effectiveness of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis in an Observational Cohort Study: Comparison of Patients According to their Eligibility for Major Randomized Clinical Trials
45. Very Low-Dose Prednisolone in Early Rheumatoid Arthritis Retards Radiographic Progression Over Two Years: A Multicenter, Double-Blind, Placebo-Controlled Trial
46. Sustained Benefits of Infliximab Therapy for Dermatologic and Articular Manifestations of Psoriatic Arthritis: Results From the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
47. Radiographic Healing With Sustained Clinical Remission in a Patient With Rheumatoid Arthritis Receiving Methotrexate Monotherapy
48. THU0653 SOCIOECONOMIC ANALYSIS OF GOLIMUMAB TREATMENT IN PATIENTS WITH RA, PSA, AND AS – NON-INTERVENTIONAL STUDY GO-NICE
49. SAT0166 GOLIMUMAB AS FIRST, SECOND OR AT LEAST THIRD BIOLOGIC AGENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) OR ANKYLOSING SPONDYLITIS (AS) – POST HOC ANALYSIS OF A NON-INTERVENTIONAL STUDY IN GERMANY
50. Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.